Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 11/20 | 0.53 |
| ▸ | CMA1 | P23946 | 4/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.50 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366612 | 0.85 | CMA1 (0.50) | ELANECMA1CAPN1MALT1 | |
| SCHEMBL31628587 | 0.85 | ELANE (0.51) | ELANECMA1CAPN1MALT1 | |
| SCHEMBL7004717 | 0.85 | ELANE (0.51) | ELANECMA1CAPN1MALT1 | |
| SCHEMBL13822216 | 0.85 | ELANE (0.55) | ELANE | |
| SCHEMBL7286279 | 0.84 | CAPN1 (0.51) | ELANECMA1CAPN1MALT1 | |
| SCHEMBL29427202 | 0.84 | ELANE (0.49) | ELANECMA1CAPN1MALT1 | |
| SCHEMBL13822217 | 0.84 | ELANE (0.53) | ELANE | |
| SCHEMBL13299695 | 0.84 | ELANE (0.57) | ELANE | |
| SCHEMBL1506200 | 0.81 | ALDH1A1 (0.62) | ELANECMA1CAPN1CTSLCTSB | |
| SCHEMBL22209363 | 0.81 | ALDH1A1 (0.62) | ELANECMA1CAPN1CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156509-A1 | Tri-peptide Inhibitors of Serine Elastases | ACCUTHERA, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156509-A1 | Tri-peptide Inhibitors of Serine Elastases | ACCUTHERA, INC. (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156509-A1 | Tri-peptide Inhibitors of Serine Elastases | SCTR, CTRC, SERPINB1 | ELANE 4/4885CMA1 18/4885CAPN1 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.